Document:

exv10w1

 

EXHIBIT 10.1

CONSULTING AGREEMENT

     THIS CONSULTING AGREEMENT (this “Agreement”), made and entered into by and between Artes
Medical, Inc., doing business as Artes Medical, a Delaware corporation qualified to do business in
California (hereinafter “Company”) and Adelbert Stagg Ph.D. (hereinafter referred to as
“Consultant”) as of September 18, 2007 (the “Effective Date”), with respect to the following facts:

RECITALS

     A. Consultant represents that it has expertise in the area of device regulatory affairs and
quality and is ready, willing, and able to provide consulting assistance to the Company on the
terms and conditions set forth herein.

     B. Company, in reliance on Consultant’s representations, is willing to engage Consultant as an
independent contractor, and not as an employee, to provide limited consultation services to the
Company on the terms and conditions set forth herein for the purpose of assisting the Company in
the establishment and oversight of procedures and systems required to ensure compliance with
applicable regulations in the areas of Regulatory Affairs and Quality.

     C. Consultant represents that he has expertise in the area of medical device regulatory
affairs and quality and is willing to provide assistance to the Company as a consultant to the
Company under the terms and conditions set forth herein.

     In consideration of the obligations herein made and undertaken, as well as other good and
valuable consideration, the sufficiency of which is hereby acknowledged, the parties, intending to
be legally bound, covenant and agree as follows:

AGREEMENT

1. Definitions

     1.1. “Company” means Artes Medical, and its employees, officers and directors, agents,
consultant or independent contractors who disclose information to Consultant pursuant to this
agreement.

     1.2. “Confidential Information” means all information and material which is proprietary to
Company, whether or not marked as “confidential” or “proprietary” and which is disclosed to or
obtained by Consultant, which relates to Company’s past, present or future research, development or
business activities. Confidential Information is all information or materials prepared by or for
Company and includes, without limitation, all of the following: designs, drawings, specifications,
techniques, models, data, source code, object code, documentation, diagrams, flow charts, research,
development, processes, procedures, “know-how,” new product or new technology information, product
prototypes, product copies, manufacturing, development or marketing techniques and materials,
development or marketing

 - 1 - 

 

timetables, strategies related to customers, suppliers or personnel, pricing policies and
financial information, and other information of a similar nature, whether or not reduced to writing
or other tangible form, and any other Trade Secrets or nonpublic business information.
Confidential Information does not include any information which (a) was in the lawful and
unrestricted possession of Consultant prior to its disclosure by Company, (b) is or becomes
generally available to the public by acts other than those of Consultant after receiving it, or (c)
has been received lawfully and in good faith by Consultant from a third party who did not derive it
from Company.

     1.3. “Trade Secrets” shall mean any scientific or technical data, information, design,
process, procedure, formula, or improvement that is commercially valuable to the Company and is not
generally known in the tissue augmentation or collagen industry.

2. Scope of Services/Hours. Consultant shall provide advisory and consulting services in
the area of Regulatory Affairs and Quality and shall perform those duties set forth on Exhibit A,
attached hereto and incorporated herein by reference. During the term of this Agreement, Consultant
shall work approximately one day per week for a period of six (6) months; and on and after March 1,
2008, on an as-needed basis by the Company, except otherwise agreed in writing by the parties
amending this Agreement. Company specifically agrees that Consultant may perform similar services
for another entity so long as such services do not violate the terms and conditions of this
Agreement and all exhibits thereto, or impede his ability to perform his duties hereunder.

3. Covenant Not to Compete. During the Term of this Agreement and for any subsequent
period of time during which Consultant continues to receive compensation from Company, Consultant
shall not, without the prior written permission of the Company, directly or indirectly (a) render
any services to any person, firm or corporation engaged in any Competitive Business (as defined
below); (b) engage in any Competitive Business for his own account; (c) become associated with or
interested in any Competitive Business as an individual, partner, shareholder, creditor, director,
officer, principal, agent, employee, trustee, consultant, advisor or in any other relationship of
capacity; (d) employ or retain, or have or cause any other person or entity to employ or retain,
any person who was employed or retained by Company or its affiliates while the Consultant was
employed by Company. However, nothing in this Agreement shall preclude Consultant from investing
his personal assets in the securities of any Competitive Business if such securities are traded on
a national stock exchange or in the over-the-counter market if such investment does not result in
his beneficially owning, at any time, more than 4.9% of the publicity-traded equity securities of
such competitor. “Competitive Business” shall mean any business or enterprise which (a) designs,
sells, manufactures, markets and/or distributes injectable material for soft tissue augmentation or
(b) engages in any other business in which the Company is or has been involved during the twelve
month period immediately prior to the termination of the Consultant’s engagement.

4. Term And Termination

     4.1. Term. This Agreement shall commence on the Effective Date, and continue for a
period of two (2) years through September 1, 2009, unless earlier terminated pursuant to the terms
of this Agreement. The parties may amend this Agreement to extend it for an additional

 - 2 - 

 

period of time following the term of this Agreement if amended in writing and signed by both
parties.

     4.2. Termination for Breach. This Agreement may be terminated by either party upon
ten (10) days’ prior written notice, if the other party breaches any term hereof and the breaching
party fails to cure such breach within the ten-day (10) period.

     4.3. Termination Without Cause. Subject to the terms of Section 5 below, either party
may terminate this Agreement at any time upon thirty (30) days’ advance written notice to the other
party.

     4.4. Survival. In the event of any termination of this Agreement, Sections 6, 7, 8, 9
and 10 hereof shall survive and continue in effect.

5. Compensation/Expenses.

     5.1. Fees. In consideration for Consultant’s consulting services to be rendered
hereunder, Company agrees to pay to Consultant the hourly sum of $275.00 per hour up to a maximum
aggregate amount of compensation of $228,000 during the term of this Agreement unless this
Agreement is amended in writing by the parties. Payment shall be made in arrears within fifteen
(15) days of receipt of the invoice from Consultant for such services, or on such terms that the
parties mutually agree. Consultant agrees to prepare records and documentation to evidence
services rendered as reasonably required by Company for auditing or other business requirements.
Company shall reimburse Consultant for reasonable and necessary out-of–pocket expenses incurred by
Contractor in carrying out the duties of Consultant; provided however, that such expenses shall be
approved in advance by Company, and Consultant shall provide receipts to the Company for such
expenses prior to receipt of any reimbursement hereunder.

     5.2. Vesting of Stock Options. Both parties acknowledge that the terms and
conditions of the Stock Option Agreements applicable to options held by Consultant provide that so
long as Consultant remains a consultant of the Company, the options held by Consultant shall become
vested and exerciseable as set forth in Consultant’s Notice of Grant(s).

6.  Independent Consultant. It is mutually understood, acknowledged, and agreed that
Consultant in entering into and performing its duties and obligations hereunder is, and at all
times shall be, an independent contractor and that the interest and responsibility of Company is to
assure that such duties and obligations are carried out and performed in a manner which is
consistent with the provisions of this Agreement. Accordingly, (i) Company shall not otherwise
have and shall not otherwise exercise any control or direction over the means, manner or method by
which such duties and obligations of Consultant are carried out and (ii) Company will not withhold
on behalf of Consultant or otherwise for income tax, social security, unemployment insurance or any
like withholding which is imposed by law or regulation, all such being the exclusive responsibility
of Consultant which Consultant hereby expressly agree to fully discharge. No partnership, joint
venture, agency or Company-employee relationship is, is intended to be, or shall be construed to
be, established by this Agreement. Consultant shall have no power to bind the Company under any
contract, arrangement or agreement, and shall have no

 - 3 - 

 

authority or power to negotiate terms of any financial agreement, equity or debt issuance, or any
other agreement between Company and any third party.

7.  Ownership Rights

     7.1. General Property. As between Company and Consultant, all right, title, and
interest in and to the progress, systems, data, or materials used or produced by Consultant in the
performance of the services called for in this Agreement shall remain or become the property of
Company.

     7.2. Intellectual Property. Consultant agree that Company shall be entitled to own
and control all proprietary technology and all financial, operating, training ideas, data,
processes, procedures and materials, including works of expression, all copyrights, all patent
rights, and all trade secret rights in such works that are developed, written, or conceived by
Consultant during the term of this Agreement, to the extent that they relate to the performance or
the requirements of this Agreement.

     7.3. Materials Furnished. All right, title, and interest in and to any Confidential
Information, mechanical drawings, sketches, documentation, programs, systems, data, and materials
furnished to Consultant by Company are and shall remain the property of Company.

8. Confidentiality and Nondisclosure

     8.1. Consent to Disclose. Consultant will hold in complete confidence and not
disclose, produce, publish, permit access to, or reveal Confidential Information disclosed
hereunder, at any time prior to Company’s intentional public disclosure of that information,
without the express prior written consent of Company.

     8.2. Exhibit B. Consultant has executed the Company’s form of Proprietary Information
and Inventions Agreement as of the date of this Agreement, which is attached as Exhibit B and
incorporated herein by this reference.

     8.3. Remedies. Consultant agrees that Company’s Confidential Information has been
developed or obtained by the investment of significant time, effort and expense and provides
Company with a significant competitive advantage in its business. If Consultant fails to comply
with any obligations hereunder, Consultant agrees that Company will suffer immediate, irreparable
harm for which monetary damages will provide inadequate compensation. Accordingly, Consultant
agrees that Company will be entitled, in addition to any other remedies available to it, at law or
in equity, to seek immediate injunctive relief to specifically enforce the terms of this Agreement.

9. Consultant Warranties. Consultant warrant that Consultant’s performance of the services
called for by this Agreement do not and will not violate any applicable law, rule, or regulation;
any contracts with third parties; or any third-party rights in any patent, trademark, copyright,
trade secret, or similar right.

10. Indemnification. Consultant hereby indemnifies and agrees to hold harmless Company,
its directors, officers, employees and agents from and against any and all claims, demands, and

 - 4 - 

 

actions, and any liabilities, damages, or expenses resulting therefrom, including court costs and
reasonable attorney fees, arising out of or relating to the negligent or intentional acts or
omissions by Consultant hereunder or any breach of the warranties made by Consultant pursuant to
Section 8 hereof. Consultant’s obligations under this section shall survive the termination of this
Agreement for any reason. Company agrees to give Consultant prompt notice of any such claim,
demand, or action and shall, to the extent Company is not adversely affected, cooperate fully with
Consultant in defense and settlement of said claim, demand, or action. Company hereby indemnifies
and agrees to hold harmless Consultant, its officers, directors, employees and agents from and
against any and all claims, demands, and actions, and any liabilities, damages, or expenses
resulting therefrom, including court costs and reasonable attorney fees, (“Losses”) arising out of
or relating to this Agreement, except to the extent that such Losses are caused in whole or in part
by the acts or omissions of Consultant. Company’s obligations under this section shall survive
the termination of this Agreement for any reason. Consultant agrees to give Company prompt notice
of any such claim, demand, or action and shall, to the extent Consultant is not adversely affected,
cooperate fully with Company in defense and settlement of said claim, demand, or action.

11. Miscellaneous.

     11.1. Relationship of the Parties. Consultant is and shall be an independent
contractor to Company, and nothing herein shall be deemed to cause this Agreement to create an
agency, partnership, or joint venture between the parties. Nothing in this Agreement shall be
interpreted or construed as creating or establishing the relationship of employer and employee
between Company and either Consultant or any employee or agent of Consultant.

     11.2. Remedies. All remedies available to either party for one or more breaches by
the other party are and shall be deemed cumulative and may be exercised separately or concurrently
without waiver of any other remedies.

     11.3. Entire Agreement, Modifications. This Agreement, together with exhibits and
schedules attached hereto, contains the entire agreement between the parties hereto with respect to
the transactions contemplated hereby, and contains all of the terms and conditions thereof and
supersedes all prior agreements and understandings relating to the subject matter hereof. No
changes or modifications of or additions to this Agreement shall be valid unless the same shall be
in writing and signed by each party hereto.

     11.4. Severability. The provisions of this Agreement shall be deemed severable and
the invalidity or unenforceability of any one or more of the provisions hereof shall not affect the
validity and enforceability of the other provisions hereof.

     11.5. Assignment. Company may assign or otherwise transfer its rights or obligations
hereunder to any affiliated entity, or any entity which shares or which is subject to common
control. Except as set forth herein, no party to this Agreement may, voluntarily or by operation
of law, assign or otherwise transfer any of his, her or its rights or obligations under this
Agreement, without obtaining the prior written consent of the other party hereto, which may be
unreasonably withheld. Any attempted assignment in violation of this Agreement shall be void and
of no effect.

 - 5 - 

 

     11.6. Successors and Assigns. This Agreement shall be binding upon and inure to the
benefit of the parties, their successors and assigns.

     11.7. Waivers. No waiver of any of the provisions of this Agreement shall be deemed
to be or shall constitute a waiver of any other provision of this Agreement, whether or not
similar, nor shall any waiver constitute a continuing waiver. No waiver of any provision of this
Agreement shall be binding on the parties hereto unless it is executed in writing by the party
making the waiver.

     11.8. Notices. All notices, requests, demands and other communications under this
Agreement shall be in writing and shall be deemed to have been duly given on the date of delivery
if delivered personally to the party to whom notice is to be given, or on the third (3rd) day after
mailing if mailed to the party to whom notice is given, by first class mail, registered or
certified, postage prepaid, and properly addressed as set forth below on the signature page.
Either party may change the address to which notices to such party are to be addressed by giving
the other party hereto written notice of such change in the manner herein set forth.

     11.9. Arbitration. In the event a dispute concerning the payment of fees to the
Consultant arises under the terms of this Agreement, such dispute shall be submitted by the parties
to arbitration. Arbitration proceedings may be commenced by either party giving the other party
written notice thereof and proceeding thereafter in accordance with the rules and procedures of the
American Arbitration Association. Any such arbitration shall take place before a single arbitrator
only in San Diego, California. Any such arbitration shall be governed by and subject to the
application laws of the State of California (including the discovery provisions of the California
Civil Code and the California Code of Civil Procedure, including specifically Section 1283.05 of
the California Code of Civil Procedure) and the then prevailing rules of the American Arbitration
Association. The arbitrator’s award in any such arbitration shall be final and binding, and a
judgment upon such award may be enforced by any court of competent jurisdiction. Relief for all
other disputes, including but not limited to intellectual property disputes, shall not be covered
by this arbitration provision and relief shall be limited to that provided by a court of competent
jurisdiction.

     11.10. Attorneys’ Fees. If either party hereto commences an arbitration or other
action against the other party to enforce any of the terms hereof or because of the breach by such
other party of any of the terms hereof, the prevailing party shall be entitled, in addition to any
other relief granted, to all costs and expenses incurred by such prevailing party in connection
with such action, including, without limitation, all reasonable attorneys’ fees, and a right to
such costs and expenses shall be deemed to have accrued upon the commencement of such action and
shall be enforceable whether or not such action is prosecuted to judgment.

     11.11. No Third-Party Benefits. None of the provisions of this Agreement shall be for
the benefit of, or enforceable by, any third-party beneficiary.

     11.12. Governing Law. This Agreement is made and shall be governed by, and construed
and enforced in accordance with, the internal laws of the State of California, without regard to
the conflict of laws principles thereof, as the same apply to agreements executed solely by
residents of California and wholly to be performed within California.

 - 6 - 

 

     11.13. Construction. In the interpretation and construction of this Agreement, the
parties acknowledge that the terms hereof reflect extensive negotiations between the parties and
that this Agreement shall not be deemed, for the purpose of construction and interpretation, that
either party drafted this Agreement.

     11.14. Venue; Submission to Jurisdiction. Each of the parties submits to the
jurisdiction of any state or federal court sitting in San Diego County, California, in any action
or proceeding arising out of or relating to this Agreement, agrees that all claims in respect of
the action or proceeding may be heard and determined in any such court, and agrees not to bring any
action or proceeding arising out of or relating to this Agreement in any other court. Each of the
parties waives any defense of inconvenient forum to the maintenance of any action or proceeding so
brought and waives any bond, surety, or other security that might be required of any other party
with respect thereto.

[the remainder of this page left intentionally blank]

 - 7 - 

 

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date set forth above.

	 	 	 	 	 
	COMPANY:	 	 
	 
	 	 	 	 
	Artes Medical, Inc.	 	 
	 
	 	 	 	 
	By:
	 	 /s/ CHRISTOPHER J. REINHARD	 	 
	 

	 	 	 	 
	Name:
	 	 Christopher J. Reinhard	 	 
	 

	 	 	 	 
	Title:
	 	 Executive Chairman	 	 
	 

	 	 

	 	 
	Address:

	 	     5870 Pacific Center Blvd	 	 
	 

	 	     San Diego, CA 92121	 	 
	 
	 	 	 	 
	CONSULTANT:	 	 
	 
	 	 	 	 
	By:

	 	/s/ ADELBERT STAGG, PH.D.	 	 
	 

	 	 	 	 
	 

	 	Adelbert Stagg, Ph.D., an Individual	 	 
	 
	 	 	 	 
	Address:

	 	      53 Monticello	 	 
	 

	 	     Irvine, CA 92620	 	 

 - 8 - 

 

Exhibit A

(Scope of Duties)

Consultant shall perform his consulting duties under the general oversight of the Company’s Chief
Executive Officer.

Duties shall include the following as requested by the CEO:

To assess, advise and assist the Company in the area of regulatory affairs for compliance with
state, federal and international regulations related to the products of Artes Medical including
without limitation, regulatory intelligence on changes to regulations that impact the Company, the
content and preparation of regulatory submissions, and other communications and interactions with
regulatory agencies.

To advise the Company on establishing quality systems for compliance with state and federal medical
device regulations including without limitation, complaint handling, medical device reporting,
problem reporting and safety surveillance (vigilance) requirements to assure that the Company is in
compliance with regulatory requirements under federal and state law, rules and regulations.

To periodically assess, advise and otherwise assist Artes Medical in relation to continued
compliance with regulations related to the quality assurance activities described above.

 - 9 - 

 

EXHIBIT B

(Proprietary Information and Inventions Agreement)

PROPRIETARY INFORMATION

AND INVENTIONS AGREEMENT

The following confirms and constitutes an agreement (this “Agreement”) between Artes Medical,
Inc., a Delaware corporation (the “Company”) and me. In consideration of my employment or
consulting relationship with the Company (the “Service Relationship”), I hereby agree as follows:

1. I understand that the Company possesses and will possess Proprietary Information (as defined
herein) which is important to its business. For purposes of this Agreement, “Proprietary
Information” is information that was or will be developed, created, or discovered by or on behalf
of the Company, or which became or will become known by, or was or is conveyed to the Company,
which has commercial value in the Company’s business. “Proprietary Information” includes, but is
not limited to, information about manuals, procedures, client lists (including the identity of the
clients on such lists and any contact and other information compiled by the Company related to such
clients), utilization data, lead lists, trade secrets, source code, object code, computer programs,
designs, technology, ideas, know-how, processes, compositions, data, techniques, improvements,
inventions (whether patentable or not), works of authorship, business and product development
plans, customers and other information concerning the Company’s actual or anticipated business,
research or development, or which is received in confidence by or for the Company from any other
person. I understand that the Service Relationship creates a relationship of confidence and trust
between the Company and me with respect to Proprietary Information.

2. I understand that the Company possesses or will possess “Company Materials” which are important
to its business. For purposes of this Agreement, “Company Materials” are documents or other media
or tangible items that contain or embody Proprietary Information or any other information
concerning the business, operations or plans of the Company, whether such documents have been
prepared by me or by others. “Company Materials” include, but are not limited to, blueprints,
drawings, photographs, charts, graphs, notebooks, client lists (including the identity of the
clients on such lists and any contact and other information compiled by the Company related to such
clients), lead lists, manuals, computer disks, tapes or printouts, sound recordings and other
printed, typewritten or handwritten documents, as well as samples, products and the like.

3. In consideration of the Service Relationship, I hereby agree as follows:

(a) All Proprietary Information and all title, patents, patent rights, copyrights, trade
secret rights, and other intellectual property and rights anywhere in the world
(collectively “Rights”) in connection therewith shall be the sole property of the Company.
I hereby assign to the Company any Rights I may have or acquire in such Proprietary
Information, including Rights to Proprietary Information created or produced by me, or
assigned to me by a third party under a valid assignment, on behalf of the Company and for
the Company’s benefit prior to commencement of the Service Relationship, whether or not
other consideration has been paid for such Rights. At all times, both during the Service
Relationship and after its termination, I will keep in confidence and trust and will not use
or disclose any Proprietary Information or anything relating to it without the prior written
consent of an officer of the Company, except as required in connection with the performance
of my duties for the Company. Disclosure restrictions of this Agreement shall not apply to
any information (i) that is generally known to the public through no fault of mine or (ii)
that I am required to disclose by law or court order; provided, however, that I use diligent
efforts to limit disclosure and provide the Company with advanced notice of such law or
court order requiring notice. I understand that nothing contained herein will prohibit an
employee from disclosing to anyone the amount of his or her wages.

 - 10 - 

 

(b) All Company Materials shall be the sole property of the Company. I agree that during my
Service Relationship, I will not remove any Company Materials from the business premises of
the Company or deliver any Company Materials to any person or entity outside the Company,
except as required in connection with the performance of my duties for the Company. I
further agree that, immediately upon the termination of the Service Relationship by me or by
the Company, for any reason (or during the Service Relationship, if so requested by the
Company), I will return, at the Company’s expense, all Company Materials, apparatus,
equipment and other physical property, or any reproduction of such property, excepting only
(i) my personal copies of records relating to my compensation; (ii) my personal copies of
any materials previously distributed generally to stockholders of the Company; and (iii) my
copy of this Agreement.

(c) I will promptly disclose in writing to an officer of the Company or any person or
persons designated by the Company’s Board of Directors, all “Inventions” (which term
includes improvements, inventions, works of authorship, trade secrets, technology, clinical
protocols, procedures, computer programs, formulas, compositions, ideas, designs, processes,
techniques, know-how and data, whether or not patentable) made or conceived or reduced to
practice or developed by me, either alone or jointly with others, during the term of the
Service Relationship which (i) are made wholly or partially with Proprietary Information of
the Company; or (ii) which are developed partially, or wholly in the course of providing
services pursuant to the Service Relationship; or (iii) relate at the time of conception or
reduction to practice to the Company’s business which involve the use of the Company’s
Proprietary Information.

(d) I agree that all Inventions which I make, conceive, reduce to practice or develop (in
whole or in part, either alone or jointly with others) during the Service Relationship,
which (i) are made wholly or partially with Proprietary Information of the Company; or (ii)
which are developed partially, or wholly in the course of providing services pursuant to the
Service Relationship; or (iii) relate at the time of conception or reduction to practice to
the Company’s business which involve the use of the Company’s Proprietary Information,
shall be the sole property of the Company to the maximum extent permitted by Section 2870 of
the California Labor Code, a copy of which is attached and I hereby assign such Inventions
and all Rights therein to the Company. The Company shall be the sole owner of all Rights in
connection therewith. No assignment in this Agreement shall extend to inventions, the
assignment of which is prohibited by Labor Code Section 2870.

(e) I agree to perform, during and after the Service Relationship, all acts deemed
reasonably necessary or desirable by the Company to permit and assist it, at the Company’s
expense, in evidencing, perfecting, obtaining, maintaining, defending and enforcing the
Company’s Rights and/or my assignment with respect to any Inventions in any and all
countries. Such acts may include, but are not limited to, execution of documents and
assistance or cooperation in legal proceedings. I hereby irrevocably designate and appoint
the Company and its duly authorized officers and agents as my agents and attorneys-in-fact
to act for and in my behalf and instead of me, to execute and file any documents and to do
all other lawfully permitted acts to further the above purposes with the same legal force
and effect as if executed by me.

(f) Any assignment of copyright hereunder includes all rights of paternity, integrity,
disclosure and withdrawal and any other rights that may be known as or referred to as “moral
rights” (collectively “Moral Rights”). To the extent such Moral Rights cannot be assigned
under applicable law and to the extent the following is allowed by the laws in the various
countries where Moral Rights exist, I hereby waive such Moral Rights and consent to any
action of the Company that would violate such Moral Rights in the absence of such consent.
I will confirm any such waivers and consents from time to time as requested by the Company.

(g) To avoid any confusion, I may, at my option, attach hereto a list of existing Inventions
to which I claim ownership as of the date of this Agreement and that I desire to
specifically clarify are not subject to this Agreement.

(h) I represent that my performance of all the terms of this Agreement will not breach any
agreement to keep in confidence proprietary information acquired by me in confidence or in
trust prior to the Service

 - 11 - 

 

Relationship. I have not entered into, and I agree I will not enter into, any agreement
either written or oral in conflict herewith or in conflict with the Service Relationship.

4. I agree that this Agreement is not an employment contract and that I have the right to resign
and the Company has the right to terminate the Service Relationship at any time, for any reason,
with or without cause, subject to the terms and conditions set forth otherwise in the agreement
that creates the Service Relationship.

5. I recognize that, in the course of the Service Relationship I will have access to confidential
information regarding the identity of Company clients as well as other client-specific information,
including information regarding contracts with the Company. I therefore agree that during the
Service Relationship and for a period of two (2) years following the cessation of the Service
Relationship, I will not, in my individual capacity or as agent for or representative of another
person or entity, directly or indirectly solicit, encourage, induce or attempt to induce any person
who is a customer with a contractual relationship with the Company to cease doing business with the
Company. I agree that a violation of the foregoing non-solicitation obligations will constitute a
material breach of this Agreement.

6. I agree that this Agreement does not purport to set forth all of the terms and conditions of the
Service Relationship, and that as an employee of and/or consultant to the Company I have
obligations to the Company which are not set forth in this Agreement.

7. I agree that my obligations under paragraphs 3(a) through 3(e) and paragraph 3(g) of this
Agreement shall continue in effect after termination of the Service Relationship, regardless of the
reason or reasons for termination, and whether such termination is voluntary or involuntary on my
part, and that the Company is entitled to communicate my obligations under this Agreement to any
future employer or potential employer of mine.

8. I agree that any dispute in the meaning, effect or validity of this Agreement shall be resolved
in accordance with the laws of the State of California without regard to the conflict of laws
provisions thereof. I further agree that if one or more provisions of this Agreement are held to
be illegal or unenforceable under applicable California law, such illegal or unenforceable
portion(s) shall be limited or excluded from this Agreement to the minimum extent required so that
this Agreement shall otherwise remain in full force and effect and enforceable in accordance with
its terms.

9. I acknowledge that any disclosure or unauthorized use of Proprietary Information will constitute
a material breach of this Agreement and cause substantial harm to the Company for which damages
would not be a fully adequate remedy, and, therefore, in the event of any such breach, in addition
to other available remedies, the Company shall have the right to seek injunctive relief to enforce
the terms of this Agreement.

10. Any disagreement between the parties relating to any interpretation, construction, performance
or breach of this Agreement, shall be settled by arbitration to be held in San Diego County,
California, in accordance with the rules then in effect of the American Arbitration Association.
The arbitrator may grant injunctions or other relief in such dispute or controversy. The decision
of the arbitrator shall be final, conclusive and binding on the parties to the arbitration.
Judgment may be entered on the arbitrator’s decision in any court having jurisdiction. The Company
and I shall each pay one-half of the costs and expenses of such arbitration, and each of us shall
separately pay our counsel fees and expenses.

11. This Agreement shall be effective as of the date I execute this Agreement and shall be binding
upon me, my heirs, executors, assigns, and administrators and shall inure to the benefit of the
Company, its subsidiaries, successors and assigns.

[REMAINDER OF THIS PAGE INTENTIONALLY LEFT BLANK]

 - 12 - 

 

          12. This Agreement can only be modified by a subsequent written agreement executed by a duly
authorized officer of the Company and me.

	 	 	 	 	 	 	 	 	 
	Dated: September 18, 2007

	 	 	 	 

(Signature)
	 	 
	 
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	Adelbert Stagg, Ph.D., an Individual	 	 
	 
	 	 	 	 	 	 	 	 
	ACCEPTED AND AGREED TO:	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	ARTES MEDICAL, INC.	 	 	 	 	 	 
	 
	 	 	 	 	 	 	 	 
	By:
	 	 	 	 	 	 	 	 
	 

	 	 

	 	 	 	 	 	 
	Its:
	 	 	 	 	 	 	 	 
	 

	 	 	 	 	 	 	 	 

 - 13 - 

 

ATTACHMENT A

	 	 	 
	Artes Medical, Inc.
	 	 
	 
	 	 
	 

	 	 
	 
	 	 
	 

	 	 
	Ladies and Gentlemen:
	 	 

     1. The following is a list of Inventions relevant to the subject matter of the services I will
be providing Artes Medical, Inc. (the “Company”) that have been made or conceived or first reduced
to practice by me alone or jointly with others prior to the Service Relationship that I desire to
clarify are not subject to the Company’s Proprietary Information and Inventions Agreement.

	 	 	 	 	 
	 

	 	 	 	No Inventions
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	See below:
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	Additional sheets attached 

     2. I propose to bring to the Service Relationship the following materials and documents of a
former employer:

	 	 	 	 	 
	 

	 	 	 	No materials or documents
	 

	 	 	 	 
	 
	 	 	 	 
	 

	 	 	 	See below:
	 

	 	 	 	 
	 
	 	 	 	 
	Date:                                         
	 	 	 	 
	 

	 	 	 	 
	 

	 	 	 	(Signature)
	 
	 	 	 	 
	 

	 	 	 	 
	 

	 	 	 	(Print or Type Name)

 - 14 - 

 

ATTACHMENT B

Section 2870. Application of provision providing that employee shall assign or offer to assign
rights in invention to employer.

(a) Any provision in an employment agreement which provides that an employee shall assign, or offer
to assign, any of his or her rights in an invention to his or her employer shall not apply to an
invention that the employee developed entirely on his or her own time without using the employer’s
equipment, supplies, facilities, or trade secret information except for those inventions that
either:

               (1) Relate at the time of conception or reduction to practice of the invention to the
employer’s business, or actual or demonstrably anticipated research or development of the employer;
or

               (2) Result from any work performed by the employee for his employer.

(b) To the extent a provision in an employment agreement purports to require an employee to assign
an invention otherwise excluded from being required to be assigned under subdivision (a), the
provision is against the public policy of this state and is unenforceable.

 - 15 -EX-4.1

 

EXHIBIT 4.1

FORM OF CERTIFICATE OF DESIGNATION

6.70% NONCUMULATIVE PERPETUAL PREFERRED STOCK, SERIES 6

     RESOLVED, that pursuant to the authority vested in the Board of Directors of
Merrill Lynch & Co., Inc., a Delaware corporation (the “Corporation”), by
Article IV of the Restated Certificate of Incorporation, as amended, of the
Corporation and in the Finance Committee of the Board of Directors by delegated
authority, a series of preferred stock of the Corporation be, and it hereby is,
created out of the authorized but unissued shares of the capital stock of the
Corporation, such series to be designated 6.70% Noncumulative Perpetual Preferred
Stock, Series 6, to consist of 65,000 shares (the “Series 6 Preferred
Stock”), par value $1.00 per share, the preferences, relative and other
rights, and qualifications, limitations or restrictions of which shall be (in
addition to those set forth in the Corporation’s Restated Articles of
Incorporation, as amended) as follows:

     Section 1. Liquidation Value. In the event of any voluntary or involuntary liquidation,
dissolution or winding up of the Corporation, the holders of the Series 6 Preferred Stock at the
time outstanding will be entitled to receive out of the assets of the Corporation available for
distribution to stockholders, before any distribution of assets is made to holders of Common Stock
or any other class of stock ranking junior to the Series 6 Preferred Stock in the distribution of
assets upon any liquidation, dissolution or winding up of the affairs of the Corporation,
liquidating distributions in the amount of $1,000 per share, plus any dividends declared thereon
and not yet paid prior to the date of liquidation.

     After payment of the full amount of the liquidating distributions to which they are entitled
pursuant to the preceding paragraph, the holders of Series 6 Preferred Stock will have no right or
claim to any of the remaining assets of the Corporation. In the event that, upon any such
voluntary or involuntary liquidation, dissolution or winding up, the available assets of the
Corporation are insufficient to pay the full amount of the liquidating distributions on all
outstanding Series 6 Preferred Stock and the corresponding amounts payable on all shares of other
classes or series of capital stock of the Corporation ranking on a parity with the Series 6
Preferred Stock in the distribution of assets upon any liquidation, dissolution or winding up of
the affairs of the Corporation, then the holders of the Series 6 Preferred Stock and such other
classes or series of capital stock shall share ratably in any such distribution of assets in
proportion to the full liquidating distributions to which they otherwise respectively would be
entitled.

     For the purposes of this Section 1, the consolidation or merger of the Corporation with or
into any other entity, or the sale, lease or conveyance of all or substantially all of the property
or business of the Corporation, shall not be deemed to constitute the liquidation, dissolution or
winding up of the Corporation.

 

 

     Section 2. Dividends.

     (a) Payment of Dividends. Holders of Series 6 Preferred Stock shall be entitled to receive,
if, when and as authorized and declared by the Board of Directors, out of assets of the Corporation
legally available therefor, cash dividends at an annual rate of 6.70% of the $1,000 liquidation
preference per share (equivalent to $67.00 per share per annum), and no more. Such noncumulative
cash dividends shall be payable, if authorized and declared, quarterly on March 30, June 30,
September 30 and December 30 of each year, or, if any such day is not a Business Day (as defined
herein), on the preceding Business Day (each such date, “Dividend Payment Date”). Each
authorized and declared dividend shall be payable to holders of record of the Series 6 Preferred
Stock as they appear on the stock books of the Corporation at the close of business on such record
date, not more than 45 calendar days nor less than 10 calendar days preceding the Dividend Payment
Date therefor, as may be determined by the Board of Directors (each such date, a “Record
Date”); provided, however, that if the date fixed for redemption of any of the
Series 6 Preferred Stock occurs after a dividend is authorized and declared but before it is paid,
such dividend shall be paid as part of the redemption price to the person to whom the redemption
price is paid. Quarterly dividend periods (each, a “Dividend Period”) shall commence on
and include the first day, and shall end on and include the last day, of the quarterly period in
which the corresponding Dividend Payment Date occurs.

     The amount of dividends payable for the first Dividend Period and for any other Dividend
Period which, as to any share of Series 6 Preferred Stock determined by reference to the issuance
date and the redemption or retirement date thereof), is greater or less than a full Dividend Period
shall be computed on the basis of the number of days elapsed in the period using a 360-day year
composed of twelve 30-day months.

     Holders of the Series 6 Preferred Stock shall not be entitled to any interest, or any sum of
money in lieu of interest, in respect of any dividend payment or payments on the Series 6 Preferred
Stock authorized and declared by the Board of Directors that may be unpaid.

     (b) Dividends Noncumulative. The right of holders of Series 6 Preferred Stock to receive
dividends is noncumulative. Accordingly, if the Board of Directors does not authorize or declare a
dividend payable in respect of any Dividend Period, holders of Series 6 Preferred Stock shall have
no right to receive a dividend in respect of such Dividend Period and the Corporation shall have no
obligation to pay a dividend in respect of such Dividend Period, whether or not dividends are
authorized and declared payable in respect of any prior or subsequent Dividend Period.

     (c) Priority as to Dividends; Limitations on Dividends on Junior Equity. If full dividends on
the Series 6 Preferred Stock for a completed Dividend Period shall not have been declared and paid,
or declared and a sum sufficient for the payment thereof shall not have been set apart for such
payments, no dividends or distributions shall be authorized, declared or paid or set aside for
payment (other than as provided in the second paragraph of this Section 2(c)) during the next
subsequent Dividend Period with respect to the Common Stock or any other stock

-2-

 

of the Corporation ranking junior to the Series 6 Preferred Stock as to dividends or amounts
upon liquidation, dissolution or winding up of the affairs of the Corporation (together with the
Common Stock, “Junior Equity”) or any stock on parity with the Series 6 Preferred Stock as
to dividends or amounts upon liquidation, dissolution or winding up of the affairs of the
Corporation (“Parity Stock”), nor shall any Junior Equity or Parity Stock be redeemed,
purchased or otherwise acquired for any consideration (or any monies to be paid to or made
available for a sinking fund for the redemption of any such stock) by the Corporation (except by
conversion into or exchange for other Junior Equity), until such time as dividends on all
outstanding Series 6 Preferred Stock for at least four consecutive Dividend Periods have been paid
in full.

     When dividends are not paid in full (or a sum sufficient for such full payment is not so set
apart) for any Dividend Period on the Series 6 Preferred Stock, all dividends declared on the
Series 6 Preferred Stock and any other series ranking on a parity as to dividends with the Series 6
Preferred Stock shall be declared pro rata so that the amount of dividends declared per share on
the Series 6 Preferred Stock and each such other series of capital stock shall in all cases bear to
each other the same ratio that full dividends, for such Dividend Period, per share of Series 6
Preferred Stock (which shall not include any accumulation in respect of unpaid dividends for prior
Dividend Periods) and full dividends, including required or permitted accumulations, if any, on the
stock of each other series ranking on a parity as to dividends with the Series 6 Preferred Stock
bear to each other.

     (d) So long as any shares of Series 6 Preferred Stock are outstanding, the Corporation shall
not authorize or issue any class or series of stock with a preference as to payment of
distributions or amounts upon liquidation, dissolution or winding up that is senior in right to the
preferences of the Series 6 Preferred Stock as to payment of distributions or amounts upon
liquidation, dissolution or winding up.

     (e) Any reference to “dividends” or “distributions” in this Section 2 shall not be deemed to
include any distribution made in connection with any voluntary or involuntary dissolution,
liquidation or winding up of the Corporation.

     Section 3. Optional Redemption. The Series 6 Preferred Stock will not be redeemable prior to
February 3, 2009. On or after February 3, 2009, the Series 6 Preferred Stock will be redeemable at
the option of the Corporation, in whole or in part, at any time or from time to time, at a cash
redemption price equal to the sum of the liquidation preference thereof plus the amount of the
declared and unpaid dividends thereon from the beginning of the Dividend Period in which the
redemption occurs to the date of redemption.

     In the event that fewer than all the outstanding shares of Series 6 Preferred Stock are to be
redeemed, the number of shares of Series 6 Preferred Stock to be redeemed shall be determined by
the Board of Directors, and the shares to be redeemed shall be determined by lot or pro rata as may
be determined by the Board of Directors or by any other method as may be determined by the Board of
Directors in its sole discretion to be equitable, provided that such method satisfies any
applicable requirements of any securities exchange (if any) on which the shares of Series 6
Preferred Stock are then listed.

-3-

 

     Unless full dividends on the Series 6 Preferred Stock in respect of the most recently
completed Dividend Period have been or contemporaneously are declared and paid or full dividends
have been declared and a sum sufficient for the payment thereof has been set apart for payment in
respect of the most recently completed Dividend Period, no Series 6 Preferred Stock shall be
redeemed unless all outstanding shares of Series 6 Preferred Stock are redeemed and the Corporation
shall not purchase or otherwise acquire any Series 6 Preferred Stock; provided, however, that the
Corporation may purchase or acquire Series 6 Preferred Stock pursuant to a purchase or exchange
offer made on the same terms to holders of all outstanding Series 6 Preferred Stock.

     The Corporation will give notice of redemption of the Series 6 Preferred Stock by publication
in a newspaper of general circulation in the City of New York, such publication to be made once a
week for two successive weeks commencing not less than 30 nor more than 60 days’ prior to the
redemption date. A failure to give such notice or any defect in the notice or in the Corporation’s
mailing will not affect the validity of the proceedings for the given redemption of any Series 6
Preferred Stock except as to the holder to whom notice was defective or not given. Each notice
shall state: (i) the redemption date; (ii) the redemption price and (iii) the number of shares of
Series 6 Preferred Stock to be redeemed.

     A notice by the Corporation pursuant to this Section 3 shall be sufficiently given if in
writing and mailed, first class postage prepaid, to each record holder of Series 6 Preferred Stock
at the holder’s address as it appears in the records of the Corporation’s transfer agent. In any
case where notice is given by mail, neither the failure to mail such notice nor any defect in the
notice to any particular holder shall affect the sufficiency of such notice, to any other holder.
Any notice mailed to a holder in the manner described above shall be deemed given on the date
mailed, whether or not the holder actually receives the notice. A notice of redemption shall be
given not less than 30 days and not more than 60 days prior to the date of redemption specified in
the notice, and shall specify (i) the redemption date, (ii) the number of Series 6 Preferred Stock
to be redeemed, (iii) the redemption price and (iv) the manner in which holders of Series 6
Preferred Stock called for redemption may obtain payment of the redemption price in respect of
those shares.

     Any shares of Series 6 Preferred Stock that are duly called for redemption pursuant to this
Section 3 shall no longer be deemed to be outstanding for any purpose from and after that time that
the Corporation shall have irrevocably deposited with the paying agent identified in the notice of
redemption funds in an amount equal to the aggregate redemption price. From and after that time,
the holders of the Series 6 Preferred Stock so called for redemption shall have no further rights
as stockholders of the Corporation and in lieu thereof shall have only the right to receive the
redemption price, without interest.

     Series 6 Preferred Stock redeemed pursuant to this Section 3 or purchased or otherwise
acquired for value by the Corporation shall, after such acquisition, have the status of authorized
and unissued shares of Preferred Stock and may be reissued by the Corporation at any time as shares
of any series of Preferred Stock other than as Series 6 Preferred Stock.

-4-

 

     Section 4. Voting Rights.

     (a) General. Except as expressly provided in this Section 4 and as required by law, holders
of Series 6 Preferred Stock shall have no voting rights. When the holders of Series 6 Preferred
Stock are entitled to vote as a separate series, each Series 6 Preferred Stock will be entitled to
40 votes and may designate up to 40 proxies, with each such proxy having the right to vote a whole
number of votes, totaling 40 votes per share of Series 6 Preferred Stock. When the holders of
Series 6 Preferred Stock are entitled to vote together as a class with any other capital stock of
the Corporation, each share of Series 6 Preferred Stock will be entitled to one vote.

     (b) Right to Elect Directors. If, at the time of any annual meeting of the Corporation’s
stockholders for the election of directors, the Corporation has failed to pay or declare and set
aside for payment all scheduled dividends during any six Dividend Periods (whether or not
consecutive) on the Series 6 Preferred Stock, the number of directors then constituting the Board
of Directors of the Corporation will be increased by two (if not already increased by two due to
failure to pay or declare and set aside dividends on any series of Preferred Stock), and the
holders of the Series 6 Preferred Stock, voting separately as a class with all other series of
Preferred Stock then entitled by the terms of such Preferred Stock to vote for additional
directors, will be entitled to elect such two additional directors to serve on the Corporation’s
Board of Directors at each such annual meeting. Each director elected by the holders of shares of
the Preferred Stock (a “Preferred Director”) shall continue to serve as such director until
the payment of all dividends on the Preferred Stock for at least four consecutive Dividend Periods,
including the Series 6 Preferred Stock. Any Preferred Director may be removed by, and shall not be
removed except by, the vote of the holders of record of the outstanding Series 6 Preferred Stock
entitled to vote, voting separately as a class with all other holders of all other series of
Preferred Stock entitled to vote on the matter, at a meeting of the Corporation’s stockholders, or
of the holders of the Series 6 Preferred Stock and all other series of Preferred Stock so entitled
to vote thereon, called for that purpose. As long as dividends on the Series 6 Preferred Stock
shall not have been paid for the preceding quarterly Dividend Period, (i) any vacancy in the office
of any Preferred Director may be filled (except as provided in the following clause (ii)) by any
instrument in writing signed by the remaining Preferred Director and filed with the Corporation,
and (ii) in the case of the removal of any Preferred Director, the vacancy may be filled by the
vote of the holders of the outstanding Series 6 Preferred Stock entitled to vote, voting together
as a single class with the holders of all other series of Preferred Stock entitled to vote on the
matter, at the same meeting at which such removal shall be voted. Each director appointed as
aforesaid by the remaining Preferred Director shall be deemed, for all purposes hereof, to be
Preferred Director. Any Preferred Director will be deemed to be an Independent Director for
purposes of the actions requiring the approval of a majority of the Independent Directors.

     (c) Certain Voting Rights. The affirmative vote or consent of the holders of at least 67% of
the outstanding voting power of each series of Preferred Stock of the Corporation, including the
Series 6 Preferred Stock, will be required (i) to create any class or series of stock which shall,
as to dividends or distribution of assets, rank prior to any outstanding series of Preferred Stock
of the Corporation other

-5-

 

than a series which shall not have any right to object to such creation or (ii) alter or
change the provisions of the Corporation’s Restated Certificate of Incorporation (including the
terms of the Series 6 Preferred Stock), including by consolidation or merger, so as to adversely
affect the voting powers, preferences or special rights of the holders of a series of Preferred
Stock of the Corporation; provided, however, that if such amendment shall not
adversely affect all series of Preferred Stock of the Corporation, such amendment need only be
approved by at least 67% of the voting power of each series of Preferred Stock adversely affected
thereby. Notwithstanding the foregoing, an alteration or change to the provisions of the
Corporation’s Restated Certificate of Incorporation shall not be deemed to affect the voting
powers, preferences or special rights of the holders of the Series 6 Preferred Stock, provided
that: (x) the Series 6 Preferred Stock remain outstanding with the terms thereof unchanged; or (y)
the Series 6 Preferred Stock are converted in a merger or consolidation transaction into shares of
the surviving or successor corporation or the direct or indirect parent of the surviving or
successor corporation having terms identical to the terms of the Series 6 Preferred Stock set forth
herein. Additionally, an increase in the amount of the authorized Preferred Stock or the creation
or issuance of any other series of Preferred Stock or an increase in the amount of authorized
shares of any such series, in each case ranking on a parity with or junior to the Series 6
Preferred Stock with respect to payment of dividends or distribution of assets upon liquidation,
dissolution or winding up, shall not be deemed to adversely affect the voting powers, preferences
or special rights of the holders of the Series 6 Preferred Stock.

     Section 5. Independent Directors.

     (a) Number; Definition. As long as any Series 6 Preferred Stock are outstanding, at least two
directors on the Board of Directors shall be Independent Directors. As used herein,
“Independent Director” means any director of the Corporation who is either (i) not a
current officer or employee of the Corporation or (ii) a Preferred Director.

     (b) Determination by Independent Directors. In determining whether any proposed action
requiring their consent is in the best interests of the Corporation, the Independent Directors
shall consider the interests of holders of both the Common Stock and the Preferred Stock,
including, without limitation, the holders of the Series 6 Preferred Stock. In considering the
interests of the holders of the Preferred Stock, including, without limitation, holders of the
Series 6 Preferred Stock, the Independent Directors shall owe the same duties that the Independent
Directors owe with respect to holders of shares of Common Stock.

     Section 6. No Conversion Rights. The holders of Series 6 Preferred Stock shall not have any
rights to convert such shares into shares of any other class or series of stock or into any other
securities of, or any interest in, the Corporation.

     Section 7. No Sinking Fund. No sinking fund shall be established for the retirement or
redemption of Series 6 Preferred Stock.

-6-

 

     Section 8. Preemptive or Subscription Rights. No holder of Series 6 Preferred Stock of the Corporation
shall, as such holder, have any preemptive right to purchase or subscribe for any additional shares
of stock of the Corporation or any other security of the Corporation that it may issue or sell.

     Section 9. No Other Rights. The Series 6 Preferred Stock shall not have any designations,
preferences or relative, participating, optional or other special rights except as set forth in the
Corporation’s Restated Certificate of Incorporation or as otherwise required by law.

     Section 10. Compliance with Applicable Law. Declaration by the Board of Directors and payment
by the Corporation of dividends to holders of the Series 6 Preferred Stock and repurchase,
redemption or other acquisition by the Corporation (or another entity as provided in subsection (a)
of Section 3 hereof) of Series 6 Preferred Stock shall be subject in all respects to any and all
restrictions and limitations placed on dividends, redemptions or other distributions by the
Corporation (or any such other entity) under (i) laws, regulations and regulatory conditions or
limitations applicable to or regarding the Corporation (or any such other entity) from time to time
and (ii) agreements with federal or state regulatory or banking authorities with respect to the
Corporation (or any such other entity) from time to time in effect.

-7-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00129-of-00352.parquet"}]]